ANALYSIS OF THE EFFECTIVENESS OF DIFFERENT TREATMENT REGIMENS FOR DRUG-RESISTANT TUBERCULOSIS IN PRYKARPATTIA. CHALLENGES OF OUR TIME

Author:

Makoyda Iryna1,Ostrovskyy Мykola1,Ostrovska Ksenia1,Todoriko Lidia2,Babliuk Ludmila1,Vepryk Tetiana1,Melnyk-Sheremeta Olha1

Affiliation:

1. IVANO-FRANKIVSK NATIONAL MEDICAL UNIVERSITY, IVANO-FRANKIVSK, UKRAINE

2. BUKOVINIAN STATE MEDICAL UNIVERSITY, CHERNIVTSI, UKRAINE

Abstract

The aim: To study the structure of adverse drug reactions and the effectiveness of treatment among patients with drug-resistant tuberculosis who follow the modified short-term and individualized treatment regimens. Materials and methods: The analysis of 138 inpatient medical records, outpatient health cards and electronic database of the patient register was conducted. Resistant strains of MTB were microbiologically verified in all the patients. All the patients underwent clinical-laboratory, instrumental microbiological, genetic-molecular (GeneXpert MTB / RIF) methods of examination, both for diagnosis and monitoring of the effectiveness of treatment. In order to prevent complications and control adverse reactions, all the patients were briefly screened for peripheral neuropathy, basic audiometry, the QTc interval was determined, visual acuity and color perception were checked. Results: At individualized treatment regimen of tuberculosis, adverse reactions were 3.5 times more common than in patients with modified short-term therapy, in 65 (68.4%) cases and in 8 (18.6%) cases, respectively. Accordingly, the effectiveness of treatment differed in both groups. Prevailing in long-term treatment were: treatment interruption treatment gap, treatment failure, continued treatment. In patients receiving short-term regimens, the cured rate was almost twice as common as in the second group. Conclusions: Timely detection cases of resistant tuberculosis and using linear probe analysis (LPA) - GenoType MTBDRplus for diagnosis of fluoroquinolone resistance, will allow the use of modified short-term treatment regimens for tuberculosis. Which in turn will reduce the number of side effects and improve the outcome of treatment.

Publisher

ALUNA

Subject

General Medicine

Reference13 articles.

1. 1. Feshchenko Yu. I. Suchasni tendentsiyi vyvchennya problem tuberkul'ozu [Up-to-date tendencies in tuberculosis research]. Ukrainian Pulmonology Journal. 2019; 1:8–24. (in Ukrainian)

2. 2. Melnyk V. M., Novozhylova I. A., Matusevych V. G. Prychyny neefektyvnoho likuvannya khvorykh na tuberkul'oz lehen' [Causes of treatment failure in patients with pulmonary tuberculosis]. Ukrainian Pulmonology Journal. 2020; 1:5–9. (in Ukrainian)

3. 3. Lytvynenko N.A., Siomak O.V., Didyk V.S. et al. Pershi rezul'taty kvazieksperymental'noho doslidzhennya shchodo likuvannya rezystentnoho do ryfampitsynu tuberkul'ozu za dopomohoyu skorochenoho povnistyu peroral'noho rezhymu z vykorystannyam novykh preparativ u Zhytomyrs'kiy oblasti, Ukrayina [Preliminary results of a quasi -experimental study of treatment of rifampin -resistant tuberculosis with an all-oral regimen containing new drugs in Zhytomyr oblast, Ukraine]. Tuberculosis, Lung diseases, HIV infection. 2020; 3 (42):17-26. (in Ukrainian)

4. 4. Lytvynenko N.A., Feshchenko Yu.I., Hamazkhina K.O. at al. Pershi rezul'taty vprovadzhennya bedakvilinu dlya khvorykh na mul'tyrezystentnyy tuberkul'oz v Ukrayini: rekomendatsiyi dlya praktychnykh likariv [First results of the introduction of bedaguiline for patients with multidrug resistens tuberculosis in Ukraine: recommendations for practical doctor resume] Tuberculosis, Lung diseases. HIV infection. 2018; 4 (35):19—26. (in Ukrainian)

5. 5. Feshchenko Yu.I., Lytvynenko N.A., Pohrebna M.V. at al. Alhorytm pryznachennya skorochenykh 12-misyachnykh rezhymiv likuvannya na osnovi linezolidu dlya khvorykh na tuberkul'oz z pre-rozshyrenoyu rezystentnistyu MBT. [Algorithm for the use of 12-month linezolid treatments in patients with pre-XDR tuberculosis] Journal of the National Academy of Medical Sciences of Ukraine. 2019; 3:278—284. (in Ukrainian)

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3